Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.

• Published in: The Lancet
• Main Authors: Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C.J., Estève, J., Ogunbiyi, O.J., Azevedo E Silva, G., Chen, W.Q., Eser, S., Engholm, G., Stiller, C.A., Monnereau, A., Woods, R.R., Visser, O., Lim, G.H., Aitken, J., Weir, H.K., Coleman, M.P.
• Other Authors: CONCORD Working Group, Bouzbid, S., Hamdi-Chérif, M., Zaidi, Z., Meguenni, K., Regagba, D., Bayo, S., Cheick Bougadari, T., Manraj, S.S., Bendahhou, K., Fabowale, A., Bradshaw, D., Somdyala, NIM, Kumcher, I., Moreno, F., Calabrano, G.H., Espinola, S.B., Carballo Quintero, B., Fita, R., Diumenjo, M.C., Laspada, W.D., Ibañez, S.G., Lima, C.A., De Souza, PCF, Del Pino, K., Laporte, C., Curado, M.P., de Oliveira, J.C., Veneziano, CLA, Veneziano, D.B., Latorre, MRDO, Tanaka, L.F., Rebelo, M.S., Santos, M.O., Galaz, J.C., Aparicio Aravena, M., Sanhueza Monsalve, J., Herrmann, D.A., Vargas, S., Herrera, V.M., Uribe, C.J., Bravo, L.E., Garcia, L.S., Arias-Ortiz, N.E., Morantes, D., Jurado, D.M., Yépez Chamorro, M.C., Delgado, S., Ramirez, M., Galán Alvarez, Y.H.
• Format: Article in Journal/Newspaper
• Language: English
• Published: 2018
• Subjects: Canada; Norway; New Zealand; Iceland
• Online Access: https://serval.unil.ch/notice/serval:BIB_E763572951C3; https://doi.org/10.1016/S0140-6736(17)33326-3

In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival as a metric of the effectiveness of health systems and to inform global policy on cancer control. CONCORD-3 updates the worldwide surveillance of cancer survival to 2014. CONCORD-3 includes individual records for 37·5 million patients diagnosed with cancer during the 15-year period 2000-14. Data were provided by 322 population-based cancer registries in 71 countries and territories, 47 of which provided data with 100% population coverage. The study includes 18 cancers or groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate, and melanoma of the skin in adults, and brain tumours, leukaemias, and lymphomas in both adults and children. Standardised quality control procedures were applied; errors were rectified by the registry concerned. We estimated 5-year net survival. Estimates were age-standardised with the International Cancer Survival Standard weights. For most cancers, 5-year net survival remains among the highest in the world in the USA and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway, and Sweden. For many cancers, Denmark is closing the survival gap with the other Nordic countries. Survival trends are generally increasing, even for some of the more lethal cancers: in some countries, survival has increased by up to 5% for cancers of the liver, pancreas, and lung. For women diagnosed during 2010-14, 5-year survival for breast cancer is now 89·5% in Australia and 90·2% in the USA, but international differences remain very wide, with levels as low as 66·1% in India. For gastrointestinal cancers, the highest levels of 5-year survival are seen in southeast Asia: in South Korea for cancers of the stomach (68·9%), colon (71·8%), and rectum (71·1%); in Japan for oesophageal cancer (36·0%); and in Taiwan for liver cancer (27·9%). By contrast, in the same world region, survival is generally lower than elsewhere for melanoma of the ...